{"id":5473,"date":"2021-03-22T10:27:01","date_gmt":"2021-03-22T17:27:01","guid":{"rendered":"https:\/\/qualigendiagnostics.com\/staging\/9074\/?p=5473"},"modified":"2022-01-28T21:55:59","modified_gmt":"2022-01-29T05:55:59","slug":"matthew-e-korenberg","status":"publish","type":"post","link":"https:\/\/qualigendiagnostics.com\/staging\/9074\/matthew-e-korenberg\/","title":{"rendered":"Matthew E. Korenberg: Director"},"content":{"rendered":"\n

Mr. Korenberg has served as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since January 2018 and before that as Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.<\/p>\n\n\n\n